Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

About Portola Pharmaceuticals

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTLA
  • CUSIP:
Key Metrics:
  • Previous Close: $20.41
  • 50 Day Moving Average: $24.41
  • 200 Day Moving Average: $25.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.50
  • P/E Growth: 0.00
  • Market Cap: $1.18B
  • Outstanding Shares: 56,501,000
  • Beta: 1.03
Additional Links:
Companies Related to Portola Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $29.40 (44.05% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetDetails
8/19/2016Morgan StanleyLower Price TargetOverweight$61.00 -> $28.00View Rating Details
8/19/2016Credit Suisse Group AGLower Price TargetNeutral$30.00 -> $25.00View Rating Details
8/19/2016Citigroup Inc.DowngradeBuy -> Neutral$40.00 -> $24.00View Rating Details
8/18/2016Cowen and CompanyReiterated RatingBuyView Rating Details
3/28/2016William BlairReiterated RatingBuyView Rating Details
3/28/2016Goldman Sachs Group Inc.DowngradeBuy -> Neutral$65.00 -> $30.00View Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
8/15/2013($0.72)($1.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
Current Year EPS Consensus Estimate: $-4.34 EPS
Next Year EPS Consensus Estimate: $-4.54 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($1.18)($1.18)($1.18)
Q4 20161($1.16)($1.16)($1.16)
Q1 20171($1.11)($1.11)($1.11)
Q2 20171($1.00)($1.00)($1.00)
Q3 20171($1.03)($1.03)($1.03)
Q4 20171($0.85)($0.85)($0.85)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Portola Pharmaceuticals (NASDAQ:PTLA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Portola Pharmaceuticals (NASDAQ:PTLA)
DateHeadline
News IconPortola Pharmaceuticals, Inc.'s (PTLA): Trend Analysis Report - Hot Stocks Point (NASDAQ:PTLA)
www.hotstockspoint.com - August 25 at 12:03 PM
News IconTime To Put On The Watch List? - Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Celldex Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:PTLA)
voiceregistrar.com - August 25 at 12:03 PM
News IconPortola Pharma Receives CRL From FDA For BLA For AndexXa; Stock Plunges (NASDAQ:PTLA)
thelakeandeswave.com - August 23 at 11:28 AM
News IconThe GEO Group Inc (NYSE:GEO) & Portola Pharmaceuticals (NASDAQ:PTLA) Are Stocks to Keep Your Eyes on (NASDAQ:PTLA)
www.newsismoney.com - August 22 at 6:52 PM
investornewswire.com logoCan Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:PTLA)
www.investornewswire.com - August 22 at 11:35 AM
finance.yahoo.com logoPortola IndexXa's Regulatory Application Validated in the EU (NASDAQ:PTLA)
finance.yahoo.com - August 22 at 11:35 AM
nasdaq.com logoRSI Alert: Portola Pharmaceuticals (PTLA) Now Oversold (NASDAQ:PTLA)
www.nasdaq.com - August 20 at 6:36 PM
streetinsider.com logoPortola Pharma (PTLA) Says IndexXa MAA Accepted for Review in Europe - StreetInsider.com (NASDAQ:PTLA)
www.streetinsider.com - August 19 at 6:53 PM
finance.yahoo.com logoCiti Sees 'Too Much Risk' In Portola Pharma, Downgrades To Neutral (NASDAQ:PTLA)
finance.yahoo.com - August 19 at 6:53 PM
finance.yahoo.com logoPortola's AndexXa Still Approvable, But It Will Take Time (NASDAQ:PTLA)
finance.yahoo.com - August 19 at 6:53 PM
thestreet.com logoPortola Pharmaceuticals (PTLA) Stock Falls, Citi Downgrades (NASDAQ:PTLA)
www.thestreet.com - August 19 at 6:52 PM
biz.yahoo.com logoPORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:PTLA)
biz.yahoo.com - August 19 at 6:52 PM
fool.com logoWhy Portola Pharmaceuticals Inc Is Plunging Today (NASDAQ:PTLA)
www.fool.com - August 19 at 9:55 AM
finance.yahoo.com logoPortola Pharmaceuticals Inc (PTLA): A Misinterpretation Discount? (NASDAQ:PTLA)
finance.yahoo.com - August 19 at 9:55 AM
streetinsider.com logoPortola Pharma (PTLA) Says IndexXa MAA Accepted for Review in Europe (NASDAQ:PTLA)
www.streetinsider.com - August 19 at 9:55 AM
fidaily.com logoPortola Pharmaceuticals, Inc. (PTLA) – Morgan Stanley Holds Rating And Sets New Price Target (NASDAQ:PTLA)
www.fidaily.com - August 19 at 9:55 AM
marketexclusive.com logoHere’s What The FDA Said To Portola Pharmaceuticals Inc (NASDAQ:PTLA) In The AndexXa CRL (NASDAQ:PTLA)
marketexclusive.com - August 19 at 9:55 AM
publicnow.com logoPortola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa™ (andexanet alfa), a Factor Xa Inhibitor Antidote (NASDAQ:PTLA)
www.publicnow.com - August 19 at 9:55 AM
schaeffersresearch.com logoBuzz Stocks: Auris Medical Holding AG, Portola Pharmaceuticals Inc, and Raptor Pharmaceutical Corp. - Schaeffers Research (blog) (NASDAQ:PTLA)
www.schaeffersresearch.com - August 18 at 7:07 PM
thestreet.com logoPortola Pharmaceuticals (PTLA) Stock Slumps on FDA Complete Response Letter (NASDAQ:PTLA)
www.thestreet.com - August 18 at 7:07 PM
finance.yahoo.com logoPORTOLA PHARMACEUTICALS INC Financials (NASDAQ:PTLA)
finance.yahoo.com - August 18 at 7:07 PM
fool.com logoIs It "Game Over" After Portola's FDA Rejection? (NASDAQ:PTLA)
www.fool.com - August 18 at 7:07 PM
nasdaq.com logoPortola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXaâ„¢ (andexanet alfa) (NASDAQ:PTLA)
m.nasdaq.com - August 18 at 10:00 AM
streetinsider.com logoPortola Pharma (PTLA) Receives CRL from FDA for Andexanet Alfa (NASDAQ:PTLA)
www.streetinsider.com - August 18 at 10:00 AM
globenewswire.com logoPortola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa) (NASDAQ:PTLA)
globenewswire.com - August 18 at 10:00 AM
zacks.com logoPortola (PTLA) Stock Down on CRL for AndexXa BLA in U.S. (NASDAQ:PTLA)
www.zacks.com - August 18 at 10:00 AM
schaeffersresearch.com logoBuzz Stocks: Auris Medical Holding AG, Portola Pharmaceuticals Inc, and Raptor Pharmaceutical Corp. (NASDAQ:PTLA)
www.schaeffersresearch.com - August 18 at 10:00 AM
finance.yahoo.com logo3:12 am Portola Pharma receives FDA Complete Response Letter for BLA for AndexXa (NASDAQ:PTLA)
finance.yahoo.com - August 18 at 10:00 AM
capitalcube.com logoPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : August 18, 2016 (NASDAQ:PTLA)
www.capitalcube.com - August 18 at 10:00 AM
marketwatch.com logoPortola Pharma plummets 21% after government fails to accept new drug (NASDAQ:PTLA)
www.marketwatch.com - August 18 at 9:59 AM
marketexclusive.com logoPortola Pharmaceuticals Inc (NASDAQ:PTLA): A Misinterpretation ... - Market Exclusive (NASDAQ:PTLA)
marketexclusive.com - August 17 at 7:18 PM
News IconNews review of 2 biotech stocks: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Medivation, Inc. (NASDAQ:MDVN) - The Voice Registrar (NASDAQ:PTLA)
voiceregistrar.com - August 16 at 7:06 PM
capitalcube.com logoETF’s with exposure to Portola Pharmaceuticals, Inc. : August 15, 2016 (NASDAQ:PTLA)
www.capitalcube.com - August 15 at 7:22 PM
fool.com logo3 Under-the-Radar Healthcare Stocks You've Never Heard of (NASDAQ:PTLA)
www.fool.com - August 13 at 9:49 AM
capitalcube.com logoPortola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:PTLA)
www.capitalcube.com - August 12 at 7:04 PM
News IconHot Stocks to Watch: Portola Pharmaceuticals Inc (NASDAQ:PTLA), TTM Technologies, Inc. (NASDAQ:TTMI) - NYSE Journal (press release) (NASDAQ:PTLA)
stockznews.com - August 10 at 7:27 PM
sg.finance.yahoo.com logoPortola Pharmaceuticals posts 2Q loss (NASDAQ:PTLA)
sg.finance.yahoo.com - August 10 at 10:04 AM
twst.com logoPortola Pharmaceuticals Inc.: Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:PTLA)
www.twst.com - August 9 at 7:14 PM
publicnow.com logoPortola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:PTLA)
www.publicnow.com - August 9 at 7:14 PM
biz.yahoo.com logoPORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (NASDAQ:PTLA)
biz.yahoo.com - August 9 at 7:14 PM
biz.yahoo.com logoPortola Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:PTLA)
biz.yahoo.com - August 9 at 7:14 PM
biz.yahoo.com logoQ2 2016 Portola Pharmaceuticals Inc Earnings Release - Time Not Supplied (NASDAQ:PTLA)
biz.yahoo.com - August 9 at 10:08 AM
equities.com logoPortola Pharmaceuticals Inc. (PTLA) is Trading Higher on Unusual Volume for August 04 - Equities.com (NASDAQ:PTLA)
www.equities.com - August 6 at 7:00 PM
streetupdates.com logoAnalysts Watching Stocks: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Portola Pharmaceuticals, Inc. (NASDAQ ... - Street Updates (NASDAQ:PTLA)
www.streetupdates.com - August 4 at 7:28 PM
stockhouse.com logoPortola Pharmaceuticals PTLA (NASDAQ:PTLA)
www.stockhouse.com - August 2 at 7:17 PM
twst.com logoPortola Pharmaceuticals Inc.: Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9 (NASDAQ:PTLA)
www.twst.com - August 2 at 7:17 PM
publicnow.com logoPortola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9 (NASDAQ:PTLA)
www.publicnow.com - August 2 at 7:17 PM
News IconTop Earnings to Watch for: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - The Voice Registrar (NASDAQ:PTLA)
voiceregistrar.com - August 1 at 6:43 PM
investornewswire.com logoExpected For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Sales Of $343.55 - Investor Newswire (NASDAQ:PTLA)
www.investornewswire.com - July 28 at 7:14 PM
capitalcube.com logoPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : July 27, 2016 (NASDAQ:PTLA)
www.capitalcube.com - July 27 at 8:12 AM

Social

Portola Pharmaceuticals (NASDAQ:PTLA) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff